Syndax Pharmaceuticals SNDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $64.86M-5.6% | $68.73M+49.8% | $45.87M+20.8% | $37.96M+89.4% | $20.04M+161% | ||
| $58.85M-25.2% | $78.64M+39.7% | $56.28M-9.6% | $62.23M+1.0% | $61.64M-5.9% | ||
| —— | $44.92M0.0% | $44.92M0.0% | $44.92M0.0% | $44.92M+48.6% | ||
| $37.59M— | —— | $44.92M+2.5% | $43.81M+6.8% | $41.03M— | ||
| $12.05M— | —— | $12.08M-12.4% | $13.79M+32.8% | $10.38M— | ||
| $4M— | —— | —— | —— | $0— | ||
| $99.07M-24.5% | $131.28M+27.1% | $103.3M-3.7% | $107.31M+3.4% | $103.8M-0.2% | ||
| $99.07M-24.5% | $131.28M+27.1% | $103.3M-3.7% | $107.31M+3.4% | $103.8M-0.2% | ||
| -$34.2M+45.3% | -$62.55M-8.9% | -$57.43M+17.2% | -$69.35M+17.2% | -$83.76M+13.1% | ||
| -52.7%+38.3pp | -91%+34.2pp | -125.2%+57.5pp | -182.7%+235pp | -417.9%+837pp | ||
| $0— | $0— | $0-100% | $4K+100% | $2K+102% | ||
| $3.56M-17.7% | $4.33M-17.9% | $5.27M-11.4% | $5.95M-17.2% | $7.18M+1.1% | ||
| -$8.47M-55.0% | -$5.47M-66.2% | -$3.29M-31.9% | -$2.49M-129% | -$1.09M-150% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $0— | —— | $0— | $0— | $0— | ||
| -$42.67M+37.3% | -$68.01M-12.0% | -$60.72M+15.5% | -$71.85M+15.3% | -$84.85M+9.9% | ||
| -65.8%+33.2pp | -99%+33.4pp | -132.4%+56.9pp | -189.3%+234pp | -423.3%+803pp | ||
| -$0.48+38.5% | -$0.78-11.4% | -$0.70+15.7% | -$0.83+15.3% | -$0.98+10.1% | ||
| -$0.48+38.5% | -$0.78-11.4% | -$0.70+15.7% | -$0.83+15.3% | -$0.98+10.1% | ||
| 88.3M+1.9% | 86.6M0.0% | 86.6M+0.3% | 86.3M+0.2% | 86.2M+0.6% | ||
| 88.3M+1.9% | 86.6M0.0% | 86.6M+0.3% | 86.3M+0.2% | 86.2M+0.6% | ||
| $0— | —— | —— | —— | $247K— | ||
| $11.85M+23.5% | $9.59M+15.8% | $8.28M+5.5% | $7.85M-2.4% | $8.05M+63.3% | ||
| $862K— | —— | $2.41M-24.9% | $3.21M-10.8% | $3.6M— | ||
| $12.19M— | —— | $12.2M-12.2% | $13.9M+32.6% | $10.49M— | ||
| $12.05M— | —— | $12.08M-12.4% | $13.79M+32.8% | $10.38M— | ||
| $56K— | $0-100% | $62K+12.7% | $55K-50.9% | $112K+273% | ||
| -$4.04M— | —— | —— | -$45.36M-50,297% | -$90K— | ||
| $2.63M-2.7% | $2.71M+28.9% | $2.1M+64.2% | $1.28M+44.5% | $885K+7.1% | ||
| $0— | —— | $0— | $0— | $0— | ||
| $2.5M— | —— | $300K0.0% | $300K-87.0% | $2.3M— | ||
| $4M— | —— | —— | —— | $0— | ||
| $4K— | —— | $3K— | $0— | $0— | ||
| $458K— | —— | -$80K-117% | $468K-14.1% | $545K— | ||
| -$5.74M-308% | $2.75M— | —— | $7.31M+563% | -$1.58M-123% | ||
| -$120K-101% | $12.59M+112% | $5.95M+59.4% | $3.73M-54.0% | $8.12M+6.8% | ||
| -$6.14M— | —— | $38K— | —— | -$45K— | ||
| -$28.35M-210% | $25.7M+2,232% | $1.1M-93.8% | $17.9M+807% | -$2.53M-122% | ||
| $3.24M— | —— | -$3.42M+86.0% | -$24.5M-248% | -$7.04M— | ||
| $2.06M-73.6% | $7.8M+8.6% | $7.18M-44.4% | $12.92M+208% | $4.19M+1,045% | ||
| -$7.84M-245% | $5.4M+23.7% | $4.36M-59.5% | $10.77M+280% | -$5.99M— | ||
| $7.92M+33.8% | $5.92M-5.8% | $6.28M+1,039% | $551K-40.8% | $930K-99.7% | ||
| $38.39M-52.9% | $81.58M+12.6% | $72.43M+72.9% | $41.89M-55.5% | $94.14M+135% | ||
| -$50.35M+27.5% | -$69.49M+1.5% | -$70.54M+19.7% | -$87.8M+7.7% | -$95.16M-65.8% | ||
| $150M— | —— | —— | —— | —— | ||
| $130K— | —— | $158K-8.1% | $172K-22.2% | $221K— | ||
| 1— | —— | —— | —— | —— | ||
| -$43.11M— | —— | -$60.48M— | —— | -$84.48M— | ||
| -$441K— | —— | $240K+199% | -$242K-166% | $364K— | ||
| -$186K+7.5% | -$201K+26.9% | -$275K+53.1% | -$586K-165% | -$221K-108% | ||
| $39.39M-37.6% | $63.12M+107% | $30.44M-66.8% | $91.71M+770% | $10.54M-97.2% | ||
| $77.78M-46.3% | $144.75M+40.5% | $103M-22.9% | $133.6M+27.6% | $104.68M-2.5% | ||
| $7.46M+40.4% | $5.31M-16.5% | $6.36M+7,560% | $83K-78.4% | $385K-87.7% | ||
| $458K-24.3% | $605K— | $0-100% | $468K-14.1% | $545K-14.0% | ||
| $64.86M-5.6% | $68.73M+49.8% | $45.87M+20.8% | $37.96M+89.4% | $20.04M+161% | ||
| $12.05M+7.1% | $11.25M-6.9% | $12.08M-12.4% | $13.79M+32.8% | $10.38M-15.6% | ||
| $7.46M— | —— | $6.36M+7,560% | $83K-78.4% | $385K— | ||
| -$34.2M+45.3% | -$62.55M-8.9% | -$57.43M+17.2% | -$69.35M+17.2% | -$83.76M+13.1% | ||
| -$30.2M— | —— | —— | —— | -$83.76M— | ||
| -$30.2M— | —— | —— | —— | -$83.76M— | ||
| -46.6%— | —— | —— | —— | -417.9%— | ||
| -$34.2M+45.3% | -$62.55M-8.9% | -$57.43M+17.2% | -$69.35M+17.2% | -$83.76M+13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.